Trial · NCT02704364
Results by group94
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 94
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change From Baseline in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis | NGM282 1.0 mg | 25.6 | Standard Error 100.3 | International units/Liter | |
| Mean Change From Baseline in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis | NGM282 3.0 mg | -9.8 | Standard Error 101.3 | International units/Liter | |
| Mean Change From Baseline in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis | Placebo | -0.6 | Standard Error 79.5 | International units/Liter | |
| Mean Percent Change From Baseline in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis | NGM282 1.0 mg | 7.1 | Standard Error 5.8 | percent change | |
| Mean Percent Change From Baseline in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis | NGM282 3.0 mg | -4.2 | Standard Error 5.9 | percent change | |
| Mean Percent Change From Baseline in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis | Placebo | -3.4 | Standard Error 6.0 | percent change | |
| Mean Rate of Change in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis | NGM282 1.0 mg | Weeks 1 through 4 | -17.7 | Standard Error 6.4 | U/L/Week |
| Mean Rate of Change in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis | NGM282 3.0 mg | Weeks 1 through 4 | -2.2 | Standard Error 6.1 | U/L/Week |
| Mean Rate of Change in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis | NGM282 1.0 mg | Weeks 5 through 12 | 11.9 | Standard Error 4.5 | U/L/Week |
| Mean Rate of Change in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis | NGM282 3.0 mg | Weeks 5 through 12 | -0.2 | Standard Error 2.2 | U/L/Week |
| Mean Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase in Patients With Primary Sclerosing Cholangitis | NGM282 1.0 mg | Aspartate aminotransferase | -0.2 | Standard Error 7.0 | units/liter |
| Mean Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase in Patients With Primary Sclerosing Cholangitis | NGM282 3.0 mg | Aspartate aminotransferase | -30.9 | Standard Error 7.0 | units/liter |
| Mean Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase in Patients With Primary Sclerosing Cholangitis | Placebo | Aspartate aminotransferase | -13.3 | Standard Error 7.1 | units/liter |
| Mean Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase in Patients With Primary Sclerosing Cholangitis | NGM282 1.0 mg | Alanine aminotransferase | 8.5 | Standard Error 10.2 | units/liter |
| Mean Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase in Patients With Primary Sclerosing Cholangitis | NGM282 3.0 mg | Alanine aminotransferase | -45.1 | Standard Error 10.4 | units/liter |
| Mean Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase in Patients With Primary Sclerosing Cholangitis | Placebo | Alanine aminotransferase | -12.1 | Standard Error 10.5 | units/liter |
| Mean Percent Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase in Patients With Primary Sclerosing Cholangitis | NGM282 1.0 mg | Aspartate aminotransferase | 2.6 | Standard Error 7.8 | percent change |
| Mean Percent Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase in Patients With Primary Sclerosing Cholangitis | NGM282 3.0 mg | Aspartate aminotransferase | -25.5 | Standard Error 7.9 | percent change |
| Mean Percent Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase in Patients With Primary Sclerosing Cholangitis | Placebo | Aspartate aminotransferase | -7.2 | Standard Error 8.0 | percent change |
| Mean Percent Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase in Patients With Primary Sclerosing Cholangitis | NGM282 1.0 mg | Alanine aminotransferase | 7.2 | Standard Error 8.1 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02704364/results